Xenetic Biosciences Inc 2025年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):Yes☐No☒ As of May 2, 2025, the number of outstanding shares of the registrant’s common stock was1,542,139. XENETIC BIOSCIENCES, INC.FORM 10-Q PART IFINANCIAL INFORMATION Item 1Condensed Consolidated Financial Statements: Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2025 and 2024 1.The Company Background XeneticBiosciences,Inc.(“Xenetic”or the“Company”),incorporated in the state of Nevada and based in Framingham,Massachusetts, is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficultto treat cancers. The Company’s proprietary Deoxyribonuclease (“DNase”) technology is designed to improve outcomes of existingtreatments, including immunotherapies, by targeting neutrophil extracellular traps (“NETs”), which are involved in cancer progression. As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,”the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly-owned subsidiaries. The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and Xenetic Biosciences(U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”),Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademarkregistrations and applications along with unregistered trademarks and service marks, including but not limited to XCART™, Going Concern and Management’s Plan Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about theCompany’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Companyhas incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. The Companybelieves that its existing resources will be adequate to fund the Company’s operations for a period of at least twelve months from thedate of the issuance of these financial statements. However, the Company anticipates it will need additional capital in the long-term topursue its business initiatives. While the Company believes that it has access to capital resources through possible public or privateequity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern, the 2.Risks and Uncertainties Impact of Global Events and Conflicts on Operations The short and long-term implications of geopolitical events and global conflicts, including those in Ukraine and the Middle East aredifficult to predict at this time. The imposition of current and future sanctions and counter sanctions may have an adverse effect on the 3.Summary of Significant Accounting Policies Preparation of Interim Financial Statements The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules andregulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurringadjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normallyincluded in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed oromitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’swholly-owned subsidiaries: Lipoxen, Xenetic Bioscienc